-+ 0.00%
-+ 0.00%
-+ 0.00%

U.S. FDA APPROVES SUBCUTANEOUS INDUCTION REGIMEN FOR ABBVIE'S SKYRIZI® (RISANKIZUMAB-RZAA) FOR ADULTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE

Reuters·10/23/2026 19:35:03